Within the fast-growing genomics universe, one of many extra compelling themes is the evolution of gene therapies – a theme the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is levered to.
Relative to passive genomics alternate traded funds, the actively managed ARKG can extra quickly regulate gene remedy publicity. For buyers, that is an thrilling prospects as a result of gene therapies are the epicenters of bettering affected person outcomes and, in some instances, cures.
A technique that ARKG suits into this equation is that extra gene remedy analysis is indicating long-read sequencing may very well be a pivotal long-term answer.
“Not too long ago, scientists on the Franics Crick Institute used CRISPR Cas9 to edit embryos and discovered off-target edits, or unintended modifications to the genome, in 16% of them. These off-target edits counsel that extra detailed sequencing methods, maybe lengthy learn sequencing, shall be obligatory to make sure the security of gene-editing,” based on a current be aware from ARK Funding Administration.
ARKG: Dodging Genomics Pitfalls
Amongst healthcare ETFs, ARKG is without doubt one of the extra dominant names in terms of enough publicity to long-read sequencing. For buyers, that is an essential attribute as a result of that know-how may help biotechnology firms keep away from among the pitfalls of gene remedy improvement and analysis.
“Including extra trepidation to the talk, a number of firms together with Blue Hen Bio have reported severe opposed occasions (SAE) from their gene remedy trials. Decoding whether or not the SAEs are a operate of gene remedy or pre-existing situations/exterior elements shall be essential. Once more, long-read sequencing, which is extra complete and dependable than short-read sequencing, might present some essential solutions,” provides ARK.
Knowledge verify the significance of long-read sequencing to each healthcare firms and buyers. There are a large variety of gene therapies at the moment in medical trials.
“Not too long ago, ARK estimated the variety of lively gene remedy medical trials at 712, 238 of them initiated in 2020. Because the shift to gene remedy trials continues, monitoring their security profiles shall be essential,” notes AKRG’s issuer.
Lengthy-read sequencing know-how will possible speed up, too. Regardless of the large development, scientists will do effectively to proceed to watch one precept.
“Gene remedy holds the promise of curing illness and revolutionizing well being care. In these early days, nevertheless, scientists should concentrate on its security,” concludes ARK.
For extra on disruptive applied sciences, go to our Disruptive Know-how Channel.
Learn extra on ETFtrends.com.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.